Health experts estimate that between 350 and 400 million people have chronic hepatitis B virus infections around the world. This virus causes 80 percent of primary liver cancers around the world. Many HBV patients develop cirrhosis of the liver.
Currently, the company’s RNAi-based candidate ARC-520 is part of a treatment investigation. The purpose is to determine whether the treatment is effective with chronic HBV infections, specifically whether it can gain functional care, or an immune clearant state that is determined by hepatitis B s-antigen negative serum without or with sero-conversion.
ARC-520 has small interfering RNAs (siRNAs) that are designed to interrupt the mRNA level. This would take place directly upstream within the reverse transcription process, which is when current standard of nucleoside and nucleotide care analogues act.
The company has already finished a Phase 1 single ascending dose study involving normal volunteers. The current investigation is a single dose Phase 2a studies as well as multiple dose Phase 2b studies for chronic HBV patients.
The conference will take place on August 6, 2015 in Boston, Massachusetts.
Targeting traffic control specialists involving equipment sales/rentals, supplies, flagging and related operations.